Articles published by Clovis Oncology, Inc.

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

December 12, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

September 21, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

September 11, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

August 08, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

July 20, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status

June 06, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

June 14, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference

May 05, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

May 04, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting

April 28, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4

April 20, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

April 08, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

March 31, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286

March 16, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

February 25, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

February 23, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call

February 10, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

January 10, 2022

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

December 09, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces Third Quarter 2021 Operating Results

November 03, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

October 20, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

October 19, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

October 07, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

September 20, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program

August 16, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces Second Quarter 2021 Operating Results

August 04, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4

July 21, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors

July 12, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine

June 28, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

June 23, 2021

From Clovis Oncology, Inc.

Via Business Wire

Tickers CLVS

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.